The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5)

MLA

Olafsdottir, Arndis F., et al. The Majority of People with Type 1 Diabetes and Multiple Daily Insulin Injections Benefit from Using Continuous Glucose Monitoring: An Analysis Based on the GOLD Randomized Trial (GOLD-5). 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1234761298&authtype=sso&custid=ns315887.

APA

Olafsdottir, A. F., Bolinder, J., Heise, T., Polonsky, W., Ekelund, M., Wijkman, M., Pivodic, A., Ahlen, E., Schwarcz, E., Nystrom, T., Hellman, J., Hirsch, I. B., & Lind, M. (2021). The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5).

Chicago

Olafsdottir, Arndis F., Jan Bolinder, Tim Heise, William Polonsky, Magnus Ekelund, Magnus Wijkman, Aldina Pivodic, et al. 2021. “The Majority of People with Type 1 Diabetes and Multiple Daily Insulin Injections Benefit from Using Continuous Glucose Monitoring: An Analysis Based on the GOLD Randomized Trial (GOLD-5).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1234761298&authtype=sso&custid=ns315887.